Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (AU:TLX)
:TLX
TLX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$17.03 - AU$31.97
Previous CloseN/A
Volume456.62K
Average Volume (3M)1.30M
Market Cap
AU$8.63B
Enterprise ValueAU$2.15B
Total Cash (Recent Filing)AU$710.35M
Total Debt (Recent Filing)AU$581.45M
Price to Earnings (P/E)170.5
Beta1.35
Next Earnings
Aug 21, 2025EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding338,248,780
10 Day Avg. Volume1,019,716
30 Day Avg. Volume1,297,434
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)28.23
Price to Sales (P/S)0.00
P/FCF Ratio-29.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$34.92Price Target Upside35.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Telix Pharmaceuticals News
PremiumCompany Announcements
Telix Pharmaceuticals Updates Director’s Interest in Securities
PremiumCompany Announcements
Telix Pharmaceuticals Hosts Investor Day in New York City
PremiumCompany Announcements
Telix Pharmaceuticals Issues New Securities to Bolster Strategic Initiatives
PremiumCompany Announcements
Telix Pharmaceuticals to Quote New Securities on ASXPremiumCompany Announcements
Telix Pharmaceuticals Issues New Equity Securities for Employee Incentives
PremiumCompany Announcements
Telix Pharmaceuticals Issues New Share Appreciation RightsPremiumCompany Announcements
Telix Pharmaceuticals Announces Director Change
PremiumCompany Announcements
Telix Pharmaceuticals’ AGM Resolutions Successfully PassedBulls Say, Bears Say
Bulls Say
EarningsTelix reported Q1 total revenue of $186MM (AU$296MM, +31% Q/Q, +62% Y/Y), which could lead to an H1 beat as consensus currently estimates AU$547MM (vs the current H1 run-rate of AU$592).
Market ExpansionIlluccix received a positive decision on the MAA in Europe and country approvals in Denmark, Ireland, Luxembourg, Malta, the Netherlands, Norway, and Sweden as well as MAA approval in the UK and Brazil.
Product ApprovalsApprovals of Zircaix and Pixclara and Illuccix reimbursement decisions ex-US could lead to increased revenue.
Bears Say
Product Revenue DelayZircaix revenue is delayed to the second half of 2025 due to the NDA resubmission requirement.
Options Prices
Currently, No data available
---
Ownership Overview
6.64% Insiders
2.92%
Mutual Funds
― Other Institutional Investors
86.26% Public Companies and
Individual Investors
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$17.03 and its highest was AU$31.97 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is AU$8.63B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 21, 2025 which is in 63 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Feb 20, 2025. The company reported AU$0.06 earnings per share for the quarter, the consensus estimate of AU$0.06 by AU$0.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.27.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 338,248,780 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of AU$0.06 in its last earnings report, expectations of AU$0.06. Following the earnings report the stock price went down -1.342%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
Telix Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$34.92 (35.62% Upside)
AU$34.92 (35.62% Upside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $65.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.13%
12-Months-Change
Fundamentals
Return on Equity
14.52%
Trailing 12-Months
Asset Growth
244.30%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TLX Company Deck
TLX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong financial performance and strategic growth through acquisitions and R&D investments. Despite potential regulatory delays and market uncertainties, Telix is well-positioned for significant expansion with an innovative product pipeline.Read More>TLX Stock 12 Month Forecast
Average Price Target
AU$34.92
▲(35.62%Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Prescient Therapeutics Limited
―